TWI708611B - 聚乙二醇化介白素-１１之組合物及方法 - Google Patents

聚乙二醇化介白素-１１之組合物及方法 Download PDF

Info

Publication number
TWI708611B
TWI708611B TW105106142A TW105106142A TWI708611B TW I708611 B TWI708611 B TW I708611B TW 105106142 A TW105106142 A TW 105106142A TW 105106142 A TW105106142 A TW 105106142A TW I708611 B TWI708611 B TW I708611B
Authority
TW
Taiwan
Prior art keywords
interleukin
polyethylene glycol
polypeptide chain
compound
item
Prior art date
Application number
TW105106142A
Other languages
English (en)
Chinese (zh)
Other versions
TW201703793A (zh
Inventor
游國明
桂林 朱
文遜 霍
耀南 劉
Original Assignee
香港商南沙生物科技（香港）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商南沙生物科技（香港）有限公司 filed Critical 香港商南沙生物科技（香港）有限公司
Publication of TW201703793A publication Critical patent/TW201703793A/zh
Application granted granted Critical
Publication of TWI708611B publication Critical patent/TWI708611B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105106142A 2015-03-03 2016-03-01 聚乙二醇化介白素-１１之組合物及方法 TWI708611B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127748P 2015-03-03 2015-03-03
US62/127,748 2015-03-03

Publications (2)

Publication Number Publication Date
TW201703793A TW201703793A (zh) 2017-02-01
TWI708611B true TWI708611B (zh) 2020-11-01

Family

ID=56848663

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105106142A TWI708611B (zh) 2015-03-03 2016-03-01 聚乙二醇化介白素-１１之組合物及方法
TW109132750A TWI849231B (zh) 2015-03-03 2016-03-01 聚乙二醇化介白素-11之組合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109132750A TWI849231B (zh) 2015-03-03 2016-03-01 聚乙二醇化介白素-11之組合物及方法

Country Status (7)

Country Link
US (4) US10335492B2 (enExample)
EP (1) EP3265479A4 (enExample)
JP (2) JP6937984B2 (enExample)
CN (2) CN107849108A (enExample)
HK (1) HK1246306A1 (enExample)
TW (2) TWI708611B (enExample)
WO (1) WO2016140983A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI708611B (zh) * 2015-03-03 2020-11-01 香港商南沙生物科技（香港）有限公司 聚乙二醇化介白素-１１之組合物及方法
US20240398843A1 (en) * 2021-09-28 2024-12-05 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Glycyrrhizin-branched polyethylene glycol conjugate for treating cancer
CN118388578B (zh) * 2024-04-01 2025-01-24 北京大学口腔医学院 一种用于聚乙二醇化蛋白质的方法、非共价聚乙二醇化蛋白及含有其的蛋白质药物和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005281302A (ja) * 2004-03-03 2005-10-13 Astellas Pharma Inc 修飾インターロイキン−１１及びそれを含有する医薬組成物
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7495087B2 (en) * 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
CN1316436A (zh) * 2000-04-06 2001-10-10 赵剑 水溶性缓释重组蛋白质的制备方法
RS20050501A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
WO2005085283A1 (ja) * 2004-03-03 2005-09-15 Yamanouchi Pharmaceutical Co., Ltd. 修飾インターロイキン−１１及びそれを含有する医薬組成物
KR101292740B1 (ko) * 2008-08-25 2013-08-05 주식회사 바이오폴리메드 인터루킨-11 유사체를 포함하는 생체중합체 결합체
JP2012528597A (ja) * 2009-06-03 2012-11-15 レガド・バイオサイエンシズ・インク 血小板グリコプロテインｖｉの核酸調節因子
JP5643824B2 (ja) * 2009-09-18 2014-12-17 プロセリクス メディスンズ ディベロプメント リミテッド 放出特性が改善されたｂａｂブロックポリマー
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2014008242A1 (en) * 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
US8963121B2 (en) * 2012-12-07 2015-02-24 Micron Technology, Inc. Vertical solid-state transducers and high voltage solid-state transducers having buried contacts and associated systems and methods
WO2014138086A1 (en) 2013-03-05 2014-09-12 Shifa Biomedical Compositions and methods for the production of virus-like particles
CN104073482A (zh) * 2013-12-30 2014-10-01 江苏众红生物工程创药研究院有限公司 聚乙二醇化的组织激肽释放酶及其制备方法和应用
TWI708611B (zh) * 2015-03-03 2020-11-01 香港商南沙生物科技（香港）有限公司 聚乙二醇化介白素-１１之組合物及方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005281302A (ja) * 2004-03-03 2005-10-13 Astellas Pharma Inc 修飾インターロイキン−１１及びそれを含有する医薬組成物
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Also Published As

Publication number Publication date
HK1246306A1 (zh) 2018-09-07
US20190365908A1 (en) 2019-12-05
US10881739B2 (en) 2021-01-05
JP6937984B2 (ja) 2021-09-22
US20210268117A1 (en) 2021-09-02
TW201703793A (zh) 2017-02-01
US10946103B2 (en) 2021-03-16
JP2018508580A (ja) 2018-03-29
JP7801104B2 (ja) 2026-01-16
US20180036418A1 (en) 2018-02-08
EP3265479A1 (en) 2018-01-10
WO2016140983A1 (en) 2016-09-09
US10335492B2 (en) 2019-07-02
TW202103728A (zh) 2021-02-01
US20190365909A1 (en) 2019-12-05
CN107849108A (zh) 2018-03-27
US11931417B2 (en) 2024-03-19
JP2021176875A (ja) 2021-11-11
TWI849231B (zh) 2024-07-21
CN122167559A (zh) 2026-06-09
EP3265479A4 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
ES2349043T3 (es) Variantes de neublastina.
EP2233504B1 (en) An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof
BR112015011583B1 (pt) Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
JP7801104B2 (ja) ポリエチレングリコール（ｐｅｇ）－インターロイキン１１（ｉｌ－１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ－ｉｌ－１１コンジュゲートを精製する方法
AU2022386489A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
WO2013138730A1 (en) Polymeric conjugates of c1-inhibitors
JP2025521100A (ja) 抗Ｎｅｃｔｉｎ－４抗体薬物複合体を含む医薬組成物及びその使用
JPH06228199A (ja) 血液脳関門通過可能なペプチド結合体
CN101627056B (zh) Y型聚乙二醇修饰的g-csf及其制备方法和应用
KR20240038735A (ko) 항-trop2 항체 약물 접합체를 함유하는 약제학적 조성물 및 이의 적용
JP2025522442A (ja) 抗体薬物複合体を含有する医薬組成物およびその使用
AU2017246404A1 (en) Conjugated C1 esterase inhibitor and uses thereof
RU2488598C2 (ru) Гормон роста, модифицированный двухцепочечным полиэтиленгликолем, способ его получения и применение
WO2019211842A1 (en) Long-acting human growth hormone-antagonists and methods of producing the same
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型（ＨｕｍａｎＧｒａｎｕｌｏｃｙｔｅ−ＣｏｌｏｎｙＳｔｉｍｕｌａｔｉｎｇＦａｃｔｏｒＩｓｏｆｏｒｍｓ）
CN101671390A (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101277715B (zh) 神经变性疾病的治疗
CN115605218A (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
CN105367629B (zh) 一种促红细胞生成素模拟肽以及其制备方法和用途
TW202600586A (zh) 獨特聚乙二醇化顆粒細胞群落刺激因子、其使用方法及其製備方法
CN120957752A (zh) 一种含有糖皮质激素受体激动剂的药物偶联物的药物组合物
JP2005281302A (ja) 修飾インターロイキン−１１及びそれを含有する医薬組成物
KR20040066712A (ko) 인간 성장 호르몬의 결합체
CN105153293A (zh) 一种促红细胞生成素模拟肽及其二聚体、以及制备方法和应用
EA021643B1 (ru) Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа